4.8 Article

PanDrugs2: prioritizing cancer therapies using integrated individual multi-omics data

Journal

NUCLEIC ACIDS RESEARCH
Volume 51, Issue W1, Pages W411-W418

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/nar/gkad412

Keywords

-

Ask authors/readers for more resources

PanDrugs2 is an upgraded version of PanDrugs that helps researchers interpret tumor molecular alterations and guide personalized treatment selection. It incorporates multi-omics analysis and considers cancer genetic dependencies, providing therapeutic options for genes that are difficult to target. PanDrugs2 generates an intuitive report to support clinical decision-making. The database has been updated, integrating 23 primary sources that support >74K drug-gene associations obtained from 4642 genes and 14 659 unique compounds. It is freely available for use.
Genomics studies routinely confront researchers with long lists of tumor alterations detected in patients. Such lists are difficult to interpret since only a minority of the alterations are relevant biomarkers for diagnosis and for designing therapeutic strategies. PanDrugs is a methodology that facilitates the interpretation of tumor molecular alterations and guides the selection of personalized treatments. To do so, PanDrugs scores gene actionability and drug feasibility to provide a prioritized evidence-based list of drugs. Here, we introduce PanDrugs2, a major upgrade of PanDrugs that, in addition to somatic variant analysis, supports a new integrated multi-omics analysis which simultaneously combines somatic and germline variants, copy number variation and gene expression data. Moreover, PanDrugs2 now considers cancer genetic dependencies to extend tumor vulnerabilities providing therapeutic options for untargetable genes. Importantly, a novel intuitive report to support clinical decision-making is generated. PanDrugs database has been updated, integrating 23 primary sources that support >74K drug-gene associations obtained from 4642 genes and 14 659 unique compounds. The database has also been reimplemented to allow semi-automatic updates to facilitate maintenance and release of future versions. PanDrugs2 does not require login and is freely available at .

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available